News
Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.
News
Your source for the latest updates, breakthroughs, and insights in drug development and manufacturing. Explore our featured stories, press releases, and event announcements to stay informed about our innovations and contributions to drug development and manufacturing advancements.
We’re Hiring: Scientific Account Manager – Biopharma
Avance Biosciences is hiring a Scientific Account Manager in Houston, TX — a great next step for PhD-level scientists ready to trade the bench for a client-facing role. Build relationships with biotech and pharma leaders, present our analytical and bioanalytical capabilities, and grow your career with hands-on mentorship and structured training. Apply today and help us connect great science with the people who need it...
Bioprocess and Cell & Gene Therapy International 2026
Avance Biosciences will exhibit at BioProcess International and Cell & Gene Therapy International 2026, highlighting analytical support for mRNA therapeutics and RNA vaccines, on/off-target analysis, biodistribution analysis, whole genome sequencing, and potency testing. Visit our team at Booth #1402 to discuss analytical strategies for advancing biologics and next-generation therapies...
New FDA Guidance Documents Resource Available
Keeping up with new FDA guidance documents can be challenging. The FDA regularly publishes new draft and final guidance covering topics ranging from drug development and manufacturing to diagnostics, biologics, cell and gene therapy, medical devices, and regulatory policy...
GUIDE-seq and NGS-based off-target analysis support genome editing safety assessment for engineered Treg therapy
GentiBio recently presented genome editing safety data during the “On- and Off-Target Method Development” session st the 2026 ASGCT Meeting, highlighting the extensive off-target characterization strategy used to support development of GNTI-122, an engineered regulatory T cell (Treg) [...]
Avance Biosciences to Exhibit at the ASGCT 2026 Annual Meeting
Avance Biosciences will be exhibiting at the ASGCT Annual Meeting in Boston, May 11–15, 2026. Visit Booth #1062 to connect with our team and learn how our bioanalytical and CMC testing services support cell and gene therapy development[...]
FDA Issues Draft Guidance on Genome Editing Safety Assessment Using NGS
The FDA’s new draft guidance on genome editing safety marks a significant step toward more standardized, data-driven evaluation of gene therapies. With next-generation sequencing (NGS) at the core, the guidance outlines clear expectations for assessing off-target effects, genomic integrity, and rare editing events, providing sponsors with a more defined regulatory path for IND and BLA submissions.
